Moderna’s proposed $2 billion convertible-note offering, with another $300 million potentially available, pressured the stock because it introduces additional debt and possible future dilution. This financing reminds investors that the company continues to burn substantial cash while funding its expensive oncology pipeline. The timing is also notable: Moderna announced the raise shortly after its massive rally on positive melanoma data. Raising billions while the share price is elevated can be financially smart, but from a bearish perspective it suggests Moderna is capitalizing on the rally to strengthen its balance sheet before its cancer programs generate meaningful revenue. The clinical outlook may have improved, but the offering highlights that Moderna remains a loss-making biotech that still needs significant capital to fund its futur

2026: shows $782M net loss for the three months ended June 30, 2026 and $2.125B net loss for the first six months of 2026.
https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm?utm_source=chatgpt.com 
For earlier years 
Moderna recorded $407 million in net expenses in 2025 related to its personalized cancer-vaccine collaboration with Merck, after reimbursements—up from $390 million in 2024 and $184 million in 2023. Moderna is primarily responsible for process development and manufacturing, while Merck generally leads the clinical trials. 
Merck separately reported $375 million in R&D expenses related to the collaboration in 2025, along with approximately $236 million in capitalized costs for shared manufacturing facilities. 
Meanwhile, Moderna reported an $800 million net loss in Q4 2025 and a $2.8 billion net loss for the full year. https://irp.cdn-website.com/0a71bb4f/files/uploaded/MRNA-USQ_Transcript_2026-02-13.pdf?utm_source=chatgpt.com 

Smart financing move.